Search results for: Jorge Mestre-Ferrandiz
Filter search results
HTA and Payment Mechanisms for New Drugs to Tackle AMR
23 September 2019
…Mestre-Ferrandiz, J., 2017. Incentives for New Drugs to Tackle Anti-Microbial Resistance. OHE Briefing. London: Office of Health Economics. RePEc. Karlsberg Schaffer, S., West, P., Towse, A., Henshall, C., Mestre-Ferrandiz, J.,…
OHE Presents at Global AMR R&D Hub Board of Members Meeting in Paris
18 December 2019
…Economics. RePEc. Ferraro, J., Towse, A. and Mestre-Ferrandiz, J., 2017. Incentives for New Drugs to Tackle Anti-Microbial Resistance. OHE Briefing. London: Office of Health Economics. RePEc. Karlsberg Schaffer, S., West,…
Victor R. Fuchs Award for 2020 Goes to Patricia Danzon
23 June 2020
…Thresholds As A Means To Achieve Appropriate Drug Prices In Rich And Poor Countries‘ and Danzon, Towse and Mestre-Ferrandiz (2015) she sets out an approach that can make the demand…
Establishing a Reasonable Price for an Orphan Drug
11 September 2020
…in clinical trials as a proxy for cost, applying the model developed by Mestre-Ferrandiz, Sussex and Towse (2012). To estimate differences in patient populations, the analysis relies on data on…
Data Governance Arrangements for Real-World Evidence in Japan
1 September 2019
…Hideo Yasunaga and Hayato Yamana through desk research, using the same pre-specified pro-forma as for the previous reports. 1 Cole,A., Garrison,L., Mestre-Ferrandiz,J., Towse,A., 2015. Data Governance Arrangements for Real-World Evidence.OHE…
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…Mestre-Ferrandiz, 2015; Bell et al., 2023; Garrison et al., 2019; Danzon, 2018). Pricing policies based on these principles would de-link price and value, and could undermine investment in high-value innovation….
The Impact of Biosimilars on Markets
24 May 2010
…Because the issues continue to be so important, however, we are presenting highlights in a blog series in advance of the publication. Publication now available for download: Mattison, N., Mestre-Ferrandiz, J….
Biosimilars: Issues Overview
1 June 2010
…the Stockholm School of Economics. Publication now available for download: Mattison, N., Mestre-Ferrandiz, J. and Towse, A. eds (2010) Biosimilars: How much entry and price competition will result? London: Office…
Biosimilars and Data Exclusivity
8 June 2010
…FDA determination of ‘interchangeablility’. Henry G. Grabowski is Professor Emeritus and Director of the Program in Pharmaceutical Health Economics, Duke University. Publication now available for download: Mattison, N., Mestre-Ferrandiz, J….